Seprafilm® for Prevention of Adhesions at Repeat Cesarean (SPARC)
Primary Purpose
Adhesion Formation After Primary Cesarean Delivery
Status
Terminated
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Seprafilm®
Control
Sponsored by
About this trial
This is an interventional prevention trial for Adhesion Formation After Primary Cesarean Delivery focused on measuring Seprafilm®, cesarean, adhesions, primary, repeat
Eligibility Criteria
Inclusion Criteria:
- Pregnant women after 24 weeks' gestation.
- First cesarean delivery.
- Age > 18 years.
- Cesarean to be performed by a participating surgeon.
- Non-closure of the visceral or parietal peritoneum.
Exclusion Criteria:
- Any prior abdominal surgery including prior cesarean, laparoscopy, appendectomy, cholecystectomy or any uterine adnexal or bowel surgery.
- Clinical diagnosis of chorioamnionitis.
- Women having tubal ligation at the time of primary cesarean.
- Inability to obtain informed consent.
Sites / Locations
- Abington Memorial Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
A
B
Arm Description
Seprafilm®
Control
Outcomes
Primary Outcome Measures
To determine if Seprafilm® decreases the incidence of adhesion formation by 50% after primary cesarean.
Secondary Outcome Measures
To determine to what extent Seprafilm® decreases the incidence of adhesion formation.
To determine the incidence of adhesion formation during repeat cesarean delivery.
To evaluate complication rates in those with Seprafilm® versus those without during repeat surgery by examining length of operating times, blood loss, bladder injuries, and Apgar scores
To determine the incidence of fertility issues in women having Seprafilm® placed during primary cesarean delivery versus those not having Seprafilm® placed. Participating women will be contacted by telephone every 4 months.
Full Information
NCT ID
NCT00697606
First Posted
June 12, 2008
Last Updated
December 29, 2015
Sponsor
Abington Memorial Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00697606
Brief Title
Seprafilm® for Prevention of Adhesions at Repeat Cesarean
Acronym
SPARC
Official Title
Randomized Double-Blind Controlled Study to Determine if Seprafilm® Reduces Adhesions After Primary Cesarean Section
Study Type
Interventional
2. Study Status
Record Verification Date
December 2015
Overall Recruitment Status
Terminated
Why Stopped
lack of funding
Study Start Date
July 2008 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
June 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Abington Memorial Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Adhesion formation is a result of abdominal and pelvic surgery and is a cause of such diseases as chronic pain syndrome, bowel obstruction and infertility. Both patients and surgeons suffer when adhesions are encountered, since the surgery becomes more intense, lengthy, and complicated. Seprafilm® has been shown to limit the formation of adhesions in gynecologic and abdominal surgery. Limited data is available on the effectiveness of Seprafilm® in the prevention of abdominal wall and pelvic adhesions at the time of cesarean section. Adhesions at the time of repeat cesarean make the surgery frustrating and complex, with difficult lysis of adhesions being the cause of morbidities such as bladder damage, increased blood loss, and longer operating times. The objective of this definitive project is to define the extent of reduction of adhesion formation of Seprafilm® when used at the time of primary cesarean section. Women undergoing primary cesarean section will be randomized for Seprafilm® application, and the incidence and grade of adhesions at repeat cesarean will be determined.
Detailed Description
This is a prospective randomized double-blinded study. Patients will be randomized prior to primary cesarean section to either the study arm (Seprafilm® placement) or control arm (nothing placed). Seprafilm® will be placed over the repaired uterine incision and over the anterior aspect of the uterus prior to closure of the fascia (2 to 3 sheets per patient). Randomization will be by opaque envelops containing group assignment.
Participants and surgeons will be blinded to group designation at the time of repeat cesarean. The surgeon will be asked to grade the adhesions at the time of repeat cesarean.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adhesion Formation After Primary Cesarean Delivery
Keywords
Seprafilm®, cesarean, adhesions, primary, repeat
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
450 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Experimental
Arm Description
Seprafilm®
Arm Title
B
Arm Type
Sham Comparator
Arm Description
Control
Intervention Type
Device
Intervention Name(s)
Seprafilm®
Intervention Description
Seprafilm® placed at time of primary cesarean
Intervention Type
Other
Intervention Name(s)
Control
Intervention Description
no Seprafilm® used at primary cesarean
Primary Outcome Measure Information:
Title
To determine if Seprafilm® decreases the incidence of adhesion formation by 50% after primary cesarean.
Time Frame
at repeat cesarean
Secondary Outcome Measure Information:
Title
To determine to what extent Seprafilm® decreases the incidence of adhesion formation.
Time Frame
at repeat cesarean
Title
To determine the incidence of adhesion formation during repeat cesarean delivery.
Time Frame
at repeat cesarean
Title
To evaluate complication rates in those with Seprafilm® versus those without during repeat surgery by examining length of operating times, blood loss, bladder injuries, and Apgar scores
Time Frame
at repeat cesarean
Title
To determine the incidence of fertility issues in women having Seprafilm® placed during primary cesarean delivery versus those not having Seprafilm® placed. Participating women will be contacted by telephone every 4 months.
Time Frame
ongoing during trial
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Pregnant women after 24 weeks' gestation.
First cesarean delivery.
Age > 18 years.
Cesarean to be performed by a participating surgeon.
Non-closure of the visceral or parietal peritoneum.
Exclusion Criteria:
Any prior abdominal surgery including prior cesarean, laparoscopy, appendectomy, cholecystectomy or any uterine adnexal or bowel surgery.
Clinical diagnosis of chorioamnionitis.
Women having tubal ligation at the time of primary cesarean.
Inability to obtain informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amy Mackey, MD
Organizational Affiliation
Abington Memorial Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mark Shahin, MD
Organizational Affiliation
Abington Memorial Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Richard Latta, MD
Organizational Affiliation
Abington Memorial Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
David Peleg, MD
Organizational Affiliation
Abington Memorial Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Abington Memorial Hospital
City
Abington
State/Province
Pennsylvania
ZIP/Postal Code
19001
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Seprafilm® for Prevention of Adhesions at Repeat Cesarean
We'll reach out to this number within 24 hrs